Costa L G, Olibet G, Murphy S D
Department of Environmental Health, University of Washington, Seattle 98195.
Toxicol Appl Pharmacol. 1988 Apr;93(2):319-28. doi: 10.1016/0041-008x(88)90132-9.
While the toxicity in insects of formamidines such as chlordimeform (CDM), its demethylated metabolite DCDM, and amitraz (AMZ) appears to involve activation of an octopamine-sensitive adenylate cyclase, their mechanism of action in mammals remains elusive. There is increasing evidence, however, that alpha 2-adrenoceptors might mediate certain effects of CDM, DCDM, and AMZ. In the present study, we investigated whether formamidines can interact directly with adrenoceptors in mouse forebrain both in vitro and after in vivo administration. Formamidines were potent inhibitors of the binding of [3H]clonidine to alpha 2-adrenoceptors with IC50's of 13 microM, 29 nM, and 130 nM for CDM, DCDM, and AMZ, respectively. Binding of [3H]yohimbine was inhibited with similar potencies. All compounds also inhibited with equal (CDM) or lower potency the binding of [3H]spiperone to dopamine D2 receptors and were weak inhibitors or inactive toward alpha 1- and beta-adrenoceptors, cholinergic muscarinic, GABAA, opiate mu, benzodiazepine, and histamine 1 receptors. Administration of formamidines to mice caused a dose-dependent decrease of [3H]clonidine binding. [3H]Clonidine binding returned to control values within 5 hr following administration of CDM and DCDM, but was still significantly decreased up to 48 hr after AMZ. Among different brain regions, [3H]clonidine binding was decreased to a larger extent in cerebral cortex, hippocampus, and midbrain. In vitro and ex vivo kinetic binding studies indicated that the effect of formamidines on alpha 2-adrenoceptors was due to a decrease in affinity and not to an alteration of the density of [3H]clonidine binding sites. The results of these biochemical studies support the hypothesis that alpha 2-adrenoceptors represent an important target for formamidine neurotoxicity in mammals.
虽然杀虫脒(CDM)、其去甲基代谢物DCDM以及双甲脒(AMZ)等甲脒类化合物对昆虫的毒性似乎涉及激活一种对章鱼胺敏感的腺苷酸环化酶,但其在哺乳动物中的作用机制仍不清楚。然而,越来越多的证据表明,α2-肾上腺素能受体可能介导CDM、DCDM和AMZ的某些效应。在本研究中,我们调查了甲脒类化合物在体外以及体内给药后是否能与小鼠前脑的肾上腺素能受体直接相互作用。甲脒类化合物是[3H]可乐定与α2-肾上腺素能受体结合的强效抑制剂,CDM、DCDM和AMZ的IC50分别为13 μM、29 nM和130 nM。[3H]育亨宾的结合也以相似的效力受到抑制。所有化合物对[3H]螺哌隆与多巴胺D2受体结合的抑制效力相同(CDM)或更低,并且对α1-和β-肾上腺素能受体、胆碱能毒蕈碱受体、GABAA受体、阿片μ受体、苯二氮䓬受体和组胺1受体是弱抑制剂或无活性。给小鼠施用甲脒类化合物导致[3H]可乐定结合呈剂量依赖性降低。施用CDM和DCDM后,[3H]可乐定结合在5小时内恢复到对照值,但在施用AMZ后长达48小时仍显著降低。在不同脑区中,[3H]可乐定结合在大脑皮层、海马体和中脑降低的程度更大。体外和离体动力学结合研究表明,甲脒类化合物对α2-肾上腺素能受体的作用是由于亲和力降低,而不是[3H]可乐定结合位点密度的改变。这些生化研究结果支持以下假设:α2-肾上腺素能受体是甲脒类化合物在哺乳动物中神经毒性的重要靶点。